The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia
Open accessPublished version of a preprint
Abstract
BACKGROUND: Coronavirus disease 2019 (Covid-19) is associated with immune dysregulation and hyperinflammation, including elevated interleukin-6 levels. The use of tocilizumab, a monoclonal antibody against the interleukin-6 receptor, has resulted in better outcomes in patients with severe Covid-19 pneumonia in case reports and retrospective observational cohort studies. Data are needed from randomized, placebo-controlled trials. METHODS: In this phase 3 trial, we randomly assigned patients who were hospitalized with severe Covid-19 pneumonia in a 2:1 ratio receive a single intravenous infusion of tocilizumab (at a dose of 8 mg per kilogram of body weight) or placebo. Approximately one quarter of the participants received a second dose of tocilizumab or placebo 8 to 24 hours after the first dose. The primary outcome was clinical status at day 28 on an ordinal scale ranging from 1 (discharged or ready for discharge) to 7 (death) in the modified intention-to-treat population, which included all the patients who had received at least one dose of tocilizumab or placebo. RESULTS: Of the 452 patients who underwent randomization, 438 (294 in the tocilizumab group and 144 in the placebo group) were included in the primary and secondary analyses. The median value for clinical status on the ordinal scale at day 28 was 1.0 (95% confidence interval [CI], 1.0 to 1.0) in the tocilizumab group and 2.0 (non-ICU hospitalization without supplemental oxygen) (95% CI, 1.0 to 4.0) in the placebo group (between-group difference, -1.0; 95% CI, -2.5 to 0; P = 0.31 by the van Elteren test). In the safety population, serious adverse events occurred in 103 of 295 patients (34.9%) in the tocilizumab group and in 55 of 143 patients (38.5%) in the placebo group. Mortality at day 28 was 19.7% in the tocilizumab group and 19.4% in the placebo group (weighted difference, 0.3 percentage points; 95% CI, -7.6 to 8.2; nominal P = 0.94). CONCLUSIONS: In this randomized trial involving hospitalized patients with severe Covid-19 pneumonia, the use of tocilizumab did not result in significantly better clinical status or lower mortality than placebo at 28 days. (Funded by F. Hoffmann-La Roche and the Department of Health and Human Services; COVACTA ClinicalTrials.gov number, NCT04320615.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical characteristics of coronavirus disease 2019 in China
Guan, W.-J., Ni, Z.-Y., Hu, Y., Liang, W.-H., Ou, C.-Q., He, J.-X., Liu, L., Shan, H., Lei, C.-L., Hui, D. S. C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2002032 · Cited by 30,246
Dexamethasone in Hospitalized Patients with Covid-19
The RECOVERY Collaborative Group (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2021436 · Cited by 11,477
Yang, X., Yu, Y., Xu, J., Shu, H., Xia, J., Liu, H., Wu, Y., Zhang, L., Yu, Z., Fang, M., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30079-5 · Cited by 10,066
Remdesivir for the Treatment of Covid-19 — Final Report
Beigel, J. H., Tomashek, K. M., Dodd, L. E., Mehta, A. K., Zingman, B. S., Kalil, A. C., Hohmann, E., Chu, H. Y., Luetkemeyer, A., Kline, S., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2007764 · Cited by 7,267
Endothelial cell infection and endotheliitis in COVID-19
Varga, Z., Flammer, A. J., Steiger, P., Haberecker, M., Andermatt, R., Zinkernagel, A. S., Mehra, M. R., Schuepbach, R. A., Ruschitzka, F., & Moch, H. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30937-5 · Cited by 6,358
Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19
Ackermann, M., Verleden, S. E., Kuehnel, M., Haverich, A., Welte, T., Laenger, F., Vanstapel, A., Werlein, C., Stark, H., Tzankov, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2015432 · Cited by 5,613
Ruan, Q., Yang, K., Wang, W., Jiang, L., & Song, J. (2020) · Intensive Care Medicine · doi:10.1007/s00134-020-05991-x · Cited by 4,898
Clinical and immunological features of severe and moderate coronavirus disease 2019
Chen, G., Wu, D., Guo, W., Cao, Y., Huang, D., Wang, H., Wang, T., Zhang, X., Chen, H., Yu, H., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci137244 · Cited by 4,750
Wiersinga, W. J., Rhodes, A., Cheng, A. C., Peacock, S. J., & Prescott, H. C. (2020) · JAMA · doi:10.1001/jama.2020.12839 · Cited by 4,609
Effective treatment of severe COVID-19 patients with tocilizumab
Xu, X., Han, M., Li, T., Sun, W., Wang, D., Fu, B., Zhou, Y., Zheng, X., Yang, Y., Li, X., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2005615117 · Cited by 2,647
An inflammatory cytokine signature predicts COVID-19 severity and survival
Del Valle, D. M., Kim-Schulze, S., Huang, H.-H., Beckmann, N. D., Nirenberg, S., Wang, B., Lavin, Y., Swartz, T. H., Madduri, D., Stock, A., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-1051-9 · Cited by 2,605
Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure
Giamarellos-Bourboulis, E. J., Netea, M. G., Rovina, N., Akinosoglou, K., Antoniadou, A., Antonakos, N., Damoraki, G., Gkavogianni, T., Adami, M.-E., Katsaounou, P., et al. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.04.009 · Cited by 2,045
Immunology of COVID-19: Current State of the Science
Vabret, N., Britton, G. J., Gruber, C., Hegde, S., Kim, J., Kuksin, M., Levantovsky, R., Malle, L., Moreira, A., Park, M. D., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.05.002 · Cited by 1,623
Remdesivir for the Treatment of Covid-19 — Preliminary Report
(2020) · New England Journal of Medicine · doi:10.1056/nejmc2022236 · Cited by 1,396
Cevik, M., Tate, M., Lloyd, O., Maraolo, A. E., Schafers, J., & Ho, A. (2021) · The Lancet Microbe · doi:10.1016/s2666-5247(20)30172-5 · Cited by 1,350
Tocilizumab treatment in COVID‐19: A single center experience
Luo, P., Liu, Y., Qiu, L., Liu, X., Liu, D., & Li, J. (2020) · Journal of Medical Virology · doi:10.1002/jmv.25801 · Cited by 1,237
Tocilizumab in patients with severe COVID-19: a retrospective cohort study
Guaraldi, G., Meschiari, M., Cozzi-Lepri, A., Milic, J., Tonelli, R., Menozzi, M., Franceschini, E., Cuomo, G., Orlando, G., Borghi, V., et al. (2020) · The Lancet Rheumatology · doi:10.1016/s2665-9913(20)30173-9 · Cited by 939
Elevated interleukin‐6 and severe COVID‐19: A meta‐analysis
Aziz, M., Fatima, R., & Assaly, R. (2020) · Journal of Medical Virology · doi:10.1002/jmv.25948 · Cited by 554
Self-citationThe vascular endothelium: the cornerstone of organ dysfunction in severe SARS-CoV-2 infection
Pons, S., Fodil, S., Azoulay, E., & Zafrani, L. (2020) · Critical Care · doi:10.1186/s13054-020-03062-7 · Cited by 517
Tocilizumab for Treatment of Mechanically Ventilated Patients With COVID-19
Somers, E. C., Eschenauer, G. A., Troost, J. P., Golob, J. L., Gandhi, T. N., Wang, L., Zhou, N., Petty, L. A., Baang, J. H., Dillman, N. O., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa954 · Cited by 497
Reappraisal of Ventilator-Free Days in Critical Care Research
Yehya, N., Harhay, M. O., Curley, M. A. Q., Schoenfeld, D. A., & Reeder, R. W. (2019) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201810-2050cp · Cited by 385
Michot, J.-M., Albiges, L., Chaput, N., Saada, V., Pommeret, F., Griscelli, F., Balleyguier, C., Besse, B., Marabelle, A., Netzer, F., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.03.300 · Cited by 330
First case of COVID-19 in a patient with multiple myeloma successfully treated with tocilizumab
Zhang, X., Song, K., Tong, F., Fei, M., Guo, H., Lu, Z., Wang, J., & Zheng, C. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020001907 · Cited by 248
A Review of Recent Advances Using Tocilizumab in the Treatment of Rheumatic Diseases
Rubbert‐Roth, A., Furst, D. E., Nebesky, J. M., Jin, A., & Berber, E. (2018) · Rheumatology and Therapy · doi:10.1007/s40744-018-0102-x · Cited by 145
Elevated interleukin‐6 is associated with severity of COVID‐19: A meta‐analysis
Zhu, J., Pang, J., Ji, P., Zhong, Z., Li, H., Li, B., & Zhang, J. (2020) · Journal of Medical Virology · doi:10.1002/jmv.26085 · Cited by 132
Antwi‐Amoabeng, D., Kanji, Z., Ford, B., Beutler, B. D., Riddle, M. S., & Siddiqui, F. A. (2020) · Journal of Medical Virology · doi:10.1002/jmv.26038 · Cited by 101
Kaye, A. G., & Siegel, R. (2020) · PeerJ · doi:10.7717/peerj.10322 · Cited by 63
Mastroianni, A., Greco, S., Apuzzo, G., Santis, S. D., Oriolo, C., Zanolini, A., Chidichimo, L., & Vangeli, V. (2020) · EClinicalMedicine · doi:10.1016/j.eclinm.2020.100410 · Cited by 33
Research works printed but not linked: 1
- 10.1016/j.diii.2020.03.010 · doi:10.1016/j.diii.2020.03.010
Cited by
Interleukin-6 receptor antagonists in critically ill patients with Covid-19.
The REMAP-CAP Investigators (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2100433 · Cited by 1,962
Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia
Salama, C., Han, J., Yau, L., Reiss, W. G., Kramer, B., Neidhart, J. D., Criner, G. J., Kaplan-Lewis, E., Baden, R., Pandit, L., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2030340 · Cited by 1,291
RECOVERY Collaborative Group (2021) · White Rose Research Online (University of Leeds, The University of Sheffield, University of York) · doi:10.17863/cam.70428 · Cited by 1,067
Drug treatments for covid-19: living systematic review and network meta-analysis
Siemieniuk, R. A., Bartoszko, J. J., Zeraatkar, D., Kum, E., Qasim, A., Díaz Martinez, J. P., Izcovich, A., Rochwerg, B., Lamontagne, F., Han, M. A., et al. (2020) · BMJ · doi:10.1136/bmj.m2980 · Cited by 846
The WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Domingo, P., Mur, I., Mateo, G. M., Gutierrez, M. D. M., Pomar, V., de Benito, N., Corbacho, N., Herrera, S., Millan, L., et al. (2021) · JAMA · doi:10.1001/jama.2021.11330 · Cited by 678
Self-citation
Metadata
- Authors
- Rosas, I. O., Bräu, N., Waters, M., Go, R. C., Hunter, B. D., Bhagani, S., Skiest, D., Aziz, M. S., Cooper, N., Douglas, I. S., Savic, S., Youngstein, T., Del Sorbo, L., Cubillo Gracian, A., De La Zerda, D. J., Ustianowski, A., Bao, M., Dimonaco, S., Graham, E., Matharu, B., Spotswood, H., Tsai, L., & Malhotra, A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-04-22
- Volume
- 384
- Issue
- 16
- Pages
- 1503-1516
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3129869280
- Cited by
- 1,125
- References
- 28
- FWCI
- 74.63
- Type
- journal article
- Language
- en
- Open access
- green
- Funders
- F. Hoffmann-La Roche
- U.S. Department of Health and Human Services (HHSO100201800036C)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.